- €116.31m
- €386.34m
- €786.44m
Brief: Guerbet Q1 Revenue Up At EUR 181.1 Mln
Brief: Gadopiclenol Marketing Authorization Dossier Submissions Accepted For Review By EMA And FDA
Brief: Guerbet Says EMA, FDA Agree To Review Gadopiclenol Marketing Authorisation
Brief: Guerbet Eyes Revenue Increase Of 2%-4% LFL In 2022
Brief: Guerbet Q4 Revenue Up At 191.1 Million Euros
Brief: Guerbet, Bracco Imaging Sign Global Strategic Collaboration Agreement For Gadopiclenol
Brief: Guerbet Q3 Sales Up At Eur 177.9 Million
Brief: Guerbet Contributes To NH TherAguix IPO By Placing Order Of €3 million
Brief: Guerbet H1 Operating Income Up At EUR 34.8 Mln
Brief: Guerbet Q2 Revenue At EUR 186.8 Mln
Brief: Guerbet Says Marc Massiot Appointed To BOD
Brief: Guerbet Q1 Revenue Down 11.5% At 176.3 Million Euros
Brief: Guerbet: South African Health Products Regulatory Authority Approves Lipiodol Ultra-Fluid
Brief: Guerbet Eyes Growing EBITDA In 2021
Brief: Guerbet FY EBITDA Down At 100.7 Million Euros
Brief: Guerbet: Positive Results For Phase III Clinical Trials Of Gadopiclenol
Brief: Guerbet FY Revenue Down At 712.3 Million Euros
Brief: Guerbet: Uk Approves Lipiodol Ultra-Fluid In Women Undergoing Infertility Assessment
Brief: Guerbet Maintains 2020 Objectives Reported With Its Half-Year Results